Clinical Trial Update: Safety and Efficacy Study of BC-DN-01 in Painful Diabetic Peripheral Neuropathy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety and efficacy study of BC-DN-01 for painful diabetic peripheral neuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Painful Diabetic Neuropathy

Drugs mentioned

• BC-DN-01

Snippet

Sponsor: BioChemics, Inc. | Conditions: Diabetic Neuropathy, Painful | Phase 1, Phase 2 | Status: WITHDRAWN